REG - IXICO plc - Notice of Results

IXICOAnnouncement

22/11/2021 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211122:nRSV0148Ta&default-theme=true

RNS Number : 0148T  IXICO plc  22 November 2021

IXICO plc

("IXICO" or the "Company")

 

Notice of results

Analyst and Investor presentations

 

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in
neuroscience, announces its audited Final Results for the year ended 30
September 2021 on Tuesday 7 December 2021.

 

Analyst briefing

A briefing open to analysts will take place remotely via video conference call
on Tuesday 7 December 2021 at 9.30am (GMT). If you would like the details of
this call please contact Walbrook PR on IXICO@walbrookpr.com
(mailto:IXICO@walbrookpr.com)

 

Investor briefing

Giulio Cerroni, CEO, and Grant Nash, CFO, will provide a live presentation
relating to the Final Results for the year ended 30 September 2021 via the
Investor Meet Company platform on Tuesday 7 December 2021 at 4:30pm (GMT).

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet IXICO
PLC via:

 

https://www.investormeetcompany.com/ixico-plc/register-investor
(https://www.investormeetcompany.com/ixico-plc/register-investor)

 

Investors who already follow IXICO PLC on the Investor Meet Company platform
will automatically be invited.

 

For further information please contact:

 

 IXICO plc                                                 +44 (0)20 3763 7498
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                  +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Russell Kerr (Sales

 Walbrook PR Ltd     IXICO@walbrookpr.com
 Paul McManus / Lianne Applegarth /      +44 (0)20 7933 8780
 Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to
advance medicine and human health by turning data into clinically meaningful
information, providing valuable new insights in neuroscience and our goal is
to be a leading proponent of artificial intelligence in medical image
analysis. We will achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform, to improve
the return on investment in drug development and reduce risk and uncertainty
in clinical trials for our pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com)  and
follow us on Twitter @IXICOnews

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFZMMMDLDGMZM